NCT05862324View on ClinicalTrials.gov

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2027

Conditions
Metastatic Solid Tumor
Interventions
BIOLOGICAL

TAC01-CLDN18.2

TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

45267

Cincinnati Cancer Center, Cincinnati

77030

MD Anderson Cancer Center, Houston

90033

University of Southern California, Los Angeles

92037

University of California San Diego, San Diego

02215

Dana Farber Cancer Institute, Boston

M5G 2C1

Princess Margaret Cancer Center, Toronto

H2X 0C1

Centre hospitalier de l'Université de Montréal, Montreal

All Listed Sponsors
lead

Triumvira Immunologics, Inc.

INDUSTRY

NCT05862324 - TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) | Biotech Hunter | Biotech Hunter